A large new study conducted in Spain and Italy found that beta blockers, drugs often used to slow the heart rate and lower blood pressure, did not provide clear benefits for heart attack patients ...

The REBOOT trial enrolled more than 8,400 patients recovering from a heart attack whose heart function was above 40% and assigned them to either take a beta blocker or no beta blocker within two weeks ...

In a recent study published in Nutrition & Diabetes, researchers performed an observational prospective cohort study, COVID-19 metabolic and nutritional consequences (COMETA), in Prague, Czech ...

Our glycemic balance is based on the ability of the pancreatic beta cells to detect glucose and secrete insulin to maintain our blood sugar levels. If these cells malfunction, the balance is broken, ...

In a groundbreaking revelation for cardiology, recent findings from the REBOOT trial challenge the long-held belief that beta blockers are essential for heart attack survivors. This international ...

A new Joslin Diabetes Center-led study has shown conclusively that two receptors in the insulin-producing beta cell do not affect developmental growth, refuting a long-held hypothesis in diabetes ...

The loss of the identity of insulin-secreting beta cells in the islet of Langerhans, a process also called beta cell dedifferentiation, has been proposed to be a main reason for the development of ...

BOSTON - (May 30, 2019) --Research from Joslin Diabetes Center has shown in mice that insulin resistance increases the proportion of aged beta-cells which are dysfunction. Such an increase in aged ...